Lantern Pharma Reports Positive Data From Preclinical Study With LP-184 In Glioblastoma

(RTTNews) - Lantern Pharma (LTRN) said a preclinical study has shown the company's drug candidate LP-184 is able to inhibit tumor growth and improve survival in animal models of glioblastoma. The company said new data reinforces that LP-184 may have clinical utility for the treatment of primary and metastatic brain cancers.

Based on the positive outcome, Lantern recently expanded its collaborative agreement with Kennedy Krieger Institute and Johns Hopkins. Under the expanded agreement, the company targets further validation of in-silico and other experimental results that support the observation that LP-184 can be an effective treatment in Glioblastoma regardless of MGMT status of the cancer.